Kopran Stock Falls to 52-Week Low of Rs.131 Amidst Continued Downtrend

On the trading day, Kopran opened with a gap up of 4.57%, reaching an intraday high of Rs.141.85. However, the stock reversed course to touch an intraday low of Rs.131, representing a 3.43% drop from the previous close. This volatility is underscored by an intraday price fluctuation of 5.07%, calculated from the weighted average price, indicating heightened trading activity and uncertainty.

The stock has been on a consecutive losing streak for seven days, resulting in a cumulative return decline of 17.09% during this period. This performance contrasts with the broader sector, where Kopran underperformed by 1.18% today. Furthermore, Kopran is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum in the short to long term.

Examining Kopran’s longer-term performance, the stock has generated a negative return of 35.82% over the past year, a stark contrast to the Sensex’s positive 9.10% return in the same timeframe. The Sensex itself is trading near its 52-week high of 85,290.06, currently at 84,657.26, and is supported by bullish moving averages with the 50-day DMA above the 200-day DMA. Mid-cap stocks are leading the market with a marginal gain of 0.02% in the BSE Mid Cap index, highlighting a divergence between Kopran’s performance and broader market trends.

Kopran’s 52-week high price stands at Rs.236.10, underscoring the extent of the current price decline. The company’s market capitalisation grade is rated at 4, reflecting its relative size and market presence within the Pharmaceuticals & Biotechnology sector. Despite this, domestic mutual funds hold a minimal stake of 0.01%, which may indicate limited institutional confidence or interest at prevailing price levels.

Financially, Kopran has exhibited subdued growth metrics over recent years. Operating profit has shown an annual rate of decline of 11.79% over the last five years. The company reported a fall in net sales by 22.2% in the quarter ending September 2025, continuing a trend of negative quarterly results for five consecutive periods. The profit after tax (PAT) for the quarter stood at a loss of Rs.9.92 crore, reflecting a decline of 234.4% compared to previous periods.

Return on capital employed (ROCE) for the half-year is recorded at 5.38%, one of the lowest in recent times, while the operating profit to interest coverage ratio for the quarter is at -2.53 times, indicating challenges in covering interest expenses from operating profits. These financial indicators highlight the pressures on Kopran’s profitability and operational efficiency.

Despite these challenges, Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, which suggests a conservative approach to leverage. The company’s ROCE of 4.7 and an enterprise value to capital employed ratio of 1.3 indicate valuation levels that are discounted relative to its peers’ historical averages. However, over the past year, profits have declined by 66.7%, reinforcing the subdued financial performance.

Over the last three years, Kopran has underperformed the BSE500 index across multiple timeframes, including one year and three months, reflecting persistent challenges in both near-term and long-term performance. The company’s financial results have been consistently negative, with the September 2024 quarter also recording losses after four consecutive negative quarters.

Market conditions for Kopran remain difficult, with the stock’s recent price action and financial metrics underscoring the pressures faced by the company within the Pharmaceuticals & Biotechnology sector. While the broader market and sector indices show resilience and positive momentum, Kopran’s stock continues to trade at levels significantly below its historical highs and key moving averages.

Investors analysing Kopran’s current situation will note the combination of declining sales, negative profitability, and subdued returns on capital, alongside a low institutional holding pattern. These factors contribute to the stock’s recent fall to its 52-week low of Rs.131, a level not seen since the previous year.

In summary, Kopran’s stock has experienced a notable decline, reaching a new 52-week low amid ongoing financial headwinds and market underperformance. The stock’s volatility and trading below all major moving averages reflect the challenges faced by the company in reversing its downward trajectory.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →